Biogen Inc. (BIIB)
|Net Income (ttm)||1.92B|
|Trading Day||July 26|
|Day's Range||322.51 - 335.00|
|52-Week Range||223.25 - 468.55|
The company is moving into three billion-dollar areas.
Biogen to Present Data from ADUHELM and Alzheimer's Disease Portfolio at 2021 Alzheimer's Association International C...
CAMBRIDGE, Mass., July 23, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it will share multiple oral and poster presentations from its Alzheimer's disease clinical development port...
Biogen's new — and controversial — Alzheimer's drug, Adhulem, made a modest $2 million in revenue in the first several weeks after its.
Biogen (NASDAQ: BIIB) launched in June a new Alzheimer's disease drug but its uptake so far has been slow, leading one notable Wall Street analyst to recommend a cautious approach towards the stock. Cos...
AT&T, Crocs, Biogen top Q2 estimates, Didi shares dip as China regulatory woes persist
#AT&T Myles Udland, Brian Sozzi, and Julie Hyman breakdown more Q2 earnings, which include: AT&T stock rising as the company topped estimates due to a push from wireless subscriber additions, Crocs beat...
Biogen (BIIB) beats second-quarter estimates for both earnings and sales and ups sales guidance for 2021.
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 24.29% and 6.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Biotech giant Biogen said that it brought in about $1.6 million in sales from its controversial Alzheimer's drug last month after it was approved by the Food and Drug Administration earlier in June.
Shares of Biogen (NASDAQ:BIIB) fell 0.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 44.64% over the past year to $5.68, which beat the estimat...
Biogen's Alzheimer's drug, Adhulem, generated $2 million in revenue in the first few weeks of its approval, the company said in its second-quarter earnings.
Biogen Inc (NASDAQ: BIIB) posted Q2 adjusted EPS of $5.68 ahead of the consensus estimate of $4.55, but quarterly profit fell around 71% Y/Y to $448.5 million as competition intensified for the Company'...
Biogen Inc on Thursday reported a 70.9% fall in quarterly profit as competition intensifies for multiple sclerosis drug Tecfidera, once the company's flagship treatment.
An open letter to the Alzheimer's disease community from our Head of Research and Development, Alfred Sandrock, M.D.,...
NOTE: ADUHELM TM (aducanumab-avwa) injection 100 mg/mL solution is indicated for the treatment of Alzheimer's disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairme...
Roche Is Discussing Alzheimer's Drug With FDA Following Regulators Controversial Approval Of Biogen's Aduhelm, CEO Says
Aduhelm is expected to be a bestseller for Biogen and was the first Alzheimer's drug to be granted “accelerated approval,” a decision the regulator's experts criticized and said there was not enough evi...
Mirimus Inc has collaborated with Biogen Inc (NASDAQ: BIIB) to develop RNAi-based therapeutics targeting multiple, undisclosed neurological disease indications. Terms of the collaboration are not discl...
Mirimus, Inc. Forms Strategic Collaboration with Biogen to Develop RNAi-Based Therapeutics for Neurological Disease I...
NEW YORK, July 21, 2021 /PRNewswire/ -- Mirimus, Inc., a pioneer in RNAi therapeutic design and CRISPR/Cas9 gene editing technology implementation, today announced a strategic collaboration with Biogen ...
Investor focus is likely to be on commercialization plans for new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports second-quarter earnings.
This biotech company could be a diamond in the rough -- for investors who can tolerate its share price volatility.
There are important things to watch with each of these stocks.
Biogen Inc. (BIIB) closed at $324.62 in the latest trading session, marking a -1.08% move from the prior day.
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 0 4 0 Somewhat Bullish 1 1 4 1 Indifferent 0 1 5 0 ...
The medical community has not been entirely convinced of the U.S. FDA's decision to approve Biogen Inc's (NASDAQ: BIIB) Aduhelm drug to treat Alzheimer's last month. Some health insurers also declined c...
Three hospitals won't administer new Alzheimer's drug
CNBC's "Squawk Box" team discusses a new setback for Alzheimer's drug as three hospitals won't administer it.
Biogen shares drop as big clinics say they won't administer controversial Alzheimer's drug
Cleveland Clinic and Mt. Sinai won't administer Aduhelm, a controversial but recently FDA-approved Alzheimer's drug.
Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FDA ‘abandoned its responsibility' in approving Biogen Alzheimer's drug: Doctor
Dr. Reshma Ramachandran, Physician-Fellow at the Yale National Clinician Scholars Program, joins Yahoo Finance to breakdown the concerns over the FDA approval of Biogen Alzheimer's drug. Watch the 2021 ...
BIIB stock is losing out today, as two major hospitals have declined to use Biogen's controversial new Alzheimer's drug on their campuses. The post BIIB Stock: The Drug Ban News That Has Biogen Stumblin...
A pair of large hospitals have declined to administer Biogen Inc's (NASDAQ: BIIB) Alzheimer's treatment Aduhelm, Wall Street Journal reported. The Cleveland Clinic and Mount Sinai Health System in New Y...
Biogen's Alzheimer's Drug Aduhelm Review Could Have Been Handled Differently, Says FDA Chief: STAT News
Acting FDA Commissioner Janet Woodcock pushed back against media questions about the agency's controversial approval of Alzheimer's treatment, Aduhelm developed by Biogen Inc (NASDAQ: BIIB) and Eisai Co...
Acting FDA Commissioner Dr. Janet Woodcock pushed back against questions from a journalist about the approval of Biogen's Alzheimer's medication, Aduhelm.
Biogen partners with InnoCare Pharma for orelabrutinib, a BTK inhibitor with the potential of treating multiple sclerosis. The drug is currently undergoing phase II study.
Biogen Inc (NASDAQ: BIIB) is paying $125 million upfront to work on InnoCare Pharma Limited's orelabrutinib, a small oral molecule Bruton's tyrosine kinase inhibitor (BTKi) for multiple sclerosis. InnoC...
Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK I...
CAMBRIDGE, Mass. and BEIJING, July 12, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and InnoCare Pharma Limited (HKEX: 09969) today announced that they have entered into a license and collaborati...
Several drugmakers have important clinical trial updates on the way.
By Brandon Rakszawski, Senior ETF Product Manager The Morningstar Wide Moat Focus Index (the “Moat Index” or “Index”) underperformed the S&P 500® Index in June (1.15% vs. 2.33%, respectively).
• Acting commissioner refers agency to inspector general
Biogen Inc. (NASDAQ:BIIB) shares came under pressure Friday after the Food and Drug Administration called for an investigation into the approval of the company's Alzheimer's treatment Aduhelm. What Happ...
“There continue to be concerns raised … regarding contacts between representatives from Biogen and FDA during the review process,” the acting commissioner wrote to acting Inspector General Christi Grimm.
Acting FDA Commissioner Woodcock asked the independent Office of the Inspector General to investigate interactions between the agency and Biogen prior to the drug's approval.
The FDA approves label update for Biogen's (BIIB) new Alzheimer's drug, Aduhelm. The updated label narrows the patient population, which is eligible for the drug.
The company faces hard questions from a House committee about the pricing of Alzheimer's disease drug Aduhelm.
Collaboration Between AbbVie, Biogen and Pfizer Creates World's Largest Browsable Resource Linking Rare Protein-Codin...
CAMBRIDGE, Mass. and NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Today, access to the world's largest browsable resource linking rare protein-coding genetic variants to human health and disease was laun...
Even with markets suffering, there were still some positives on Wall Street.
Biogen Inc. (NASDAQ:BIIB) shares are lower after the company announced an updated label for its recently-approved Alzheimer's treatment Aduhelm. What Happened: Biogen, which is partnering with Japan's E...
FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials
ADUHELM should be initiated in patients with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia ADUHELM should be initiated in patients with mild cognitive impairment due ...
Breaking down the costs of Biogen's billion-dollar Alzheimer's drug
CNBC's Meg Tirrell reports on the controversy over Biogen's Alzheimer's drug, which costs an average of $56,000 per year.
An unusually lenient FDA is a knife that cuts both ways for Biogen.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treati... [Read more...]
|IPO Date |
Sep 16, 1991
|Stock Exchange |
|Ticker Symbol |
In 2020, Biogen's revenue was $13.44 billion, a decrease of -6.49% compared to the previous year's $14.38 billion. Earnings were $4.00 billion, a decrease of -32.06%.
According to 33 analysts, the average rating for Biogen stock is "Hold." The 12-month stock price forecast is 404.41, which is an increase of 21.84% from the latest price.